Circadian variability of fibrinolytic markers and endothelial function in patients with obstructive sleep apnea

Sleep

Volumn 37, Issue 2, 2014, Pages 359-367

  Bagai, Kanika ^a   Muldowney III, James A S ^b   Song, Yanna ^b   Wang, Lily ^b   Bagai, Jayant ^b   Artibee, Kay J ^a   Vaughan, Douglas E ^c   Malow, Beth A ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Endothelial function; Fibrinolytic activity; OSA

Indexed keywords

BIOLOGICAL MARKER; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; APNEA HYPOPNEA INDEX; ARTICLE; BODY MASS; BRACHIAL ARTERY; CARDIOVASCULAR DISEASE; CIRCADIAN RHYTHM; CLINICAL ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; ENDOTHELIUM; FEMALE; FIBRINOLYSIS; HUMAN; INTERMITTENT HYPOXIA; MALE; MIDDLE AGED; POLYSOMNOGRAPHY; PRIORITY JOURNAL; PULSE WAVE; RADIAL ARTERY; SLEEP DISORDERED BREATHING; VASODILATATION;

ENDOTHELIAL FUNCTION; FIBRINOLYTIC ACTIVITY; OSA;

BIOLOGICAL MARKERS; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CIRCADIAN RHYTHM; CROSS-SECTIONAL STUDIES; ENDOTHELIAL CELLS; FEMALE; HUMANS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYSOMNOGRAPHY; SLEEP; SLEEP APNEA, OBSTRUCTIVE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84893484207     PISSN: 01618105     EISSN: 15509109     Source Type: Journal    
DOI: 10.5665/sleep.3414     Document Type: Article

References (53)

1. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation; 121:e46-215.
2. Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008;117:e25-146.
3. Dyken ME, Somers VK, Yamada T, Ren ZY, Zimmerman MB. Investigating the relationship between stroke and obstructive sleep apnea. Stroke 1996;27:401-7.
4. Bassetti C, Aldrich MS. Sleep apnea in acute cerebrovascular diseases: Final report on 128 patients. Sleep 1999;22:217-23.
5. Bassetti C, Aldrich MS, Chervin RD, Quint D. Sleep apnea in pat ischemic attack and stroke: A prospective study of 59 patients. Neurology 1996;47:1167-73.
6. Bassetti CL, Milanova M, Gugger M. Sleep-disordered breathing and acute ischemic stroke: diagnosis, risk factors, treatment, evolution, and long-term clinical outcome. Stroke 2006;37:967-72.
7. Yaggi HK, Concato J, Kernan WN, Lichtman JH, Brass LM, Mohsenin V. Obstructive sleep apnea as a risk factor for stroke and death. N Engl J Med 2005;353:2034-41.
8. Shahar E, Whitney CW, Redline S, et al. Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health Study. Am J Respir Crit Care Med 2001;163:19-25.
9. Mohsenin V, Valor R. Sleep apnea in patients with hemispheric stroke. Arch Phys Med Rehabil 1995;76:71-6.
10. Peker Y, Carlson J, Hedner J. Increased incidence of coronary artery disease in sleep apnoea: a long-term follow-up. Eur Respir J 2006;28:596-602.
11. Marin JM, Carrizo SJ, Vicente E, Agusti AG. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 2005;365:1046-53.
12. Collet JP, Montalescot G, Vicaut E, et al. Acute release of plasminogen activator inhibitor-1 in ST-segment elevation myocardial infarction predicts mortality. Circulation 2003;108:391-4.
13. Scarabin PY, Aillaud MF, Amouyel P, et al. Associations of fibrinogen, factor VII and PAI-1 with baseline findings among 10, 500 male participants in a prospective study of myocardial infarction-the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction. Thromb Haemost 1998;80:749-56.
14. De Taeye B, Smith LH, Vaughan DE. Plasminogen activator inhibitor-1: a common denominator in obesity, diabetes and cardiovascular disease. Curr Opin Pharmacol 2005;5:149-54.
15. Angleton P, Chandler WL, Schmer G. Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1). Circulation 1989;79:101-6.
16. Urano T, Sumiyoshi K, Nakamura M, Mori T, Takada Y, Takada A. Fluctuation of tPA and PAI-1 antigen levels in plasma: difference of their fluctuation patterns between male and female. Thromb Res 1990;60:133-9.
17. Juhan-Vague I, Alessi MC, Raccah D, et al. Daytime fluctuations of plasminogen activator inhibitor 1 (PAI-1) in populations with high PAI-1 levels. Thromb Haemost 1992;67:76-82.
18. Andreotti F, Kluft C. Circadian variation of fibrinolytic activity in blood. Chronobiol Int 1991;8:336-51.
19. Brown NJ, Agirbasli MA, Williams GH, Litchfield WR, Vaughan DE. Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1. Hypertension 1998;32:965-71.
20. Johansson L, Jansson JH, Boman K, Nilsson TK, Stegmayr B, Hallmans G. Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke. Stroke 2000;31:26-32.
21. Wiklund PG, Nilsson L, Ardnor SN, et al. Plasminogen activator inhibitor-1 4G/5G polymorphism and risk of stroke: replicated findings in two nested case-control studies based on independent cohorts. Stroke 2005;36:1661-5.
22. Juhan-Vague I, Pyke SD, Alessi MC, Jespersen J, Haverkate F, Thompson SG. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. Circulation 1996;94:2057-63.
23. Muller JE, Tofler GH, Stone PH. Circadian variation and triggers of onset of acute cardiovascular disease. Circulation 1989;79:733-43.
24. von Kanel R, Loredo JS, Ancoli-Israel S, Mills PJ, Dimsdale JE. Elevated plasminogen activator inhibitor 1 in sleep apnea and its relation to the metabolic syndrome: an investigation in 2 different study samples. Metabolism 2007;56:969-76.
25. Zamarron C, Ricoy J, Riveiro A, Gude F. Plasminogen activator inhibitor-1 in obstructive sleep apnea patients with and without hypertension. Lung 2008;186:151-6.
26. Marfaing-Koka A, Roisman G, Nedelcoux H, Barbet C, Escourrou P, Bourgin P. Vasculopathy in sleep disordered breathing: PAI-1 and E-selectine correlate with SAS severity. Sleep 2006;29(Abstract Supplement):A205.
27. Vogel RA. Heads and hearts - The endothelial connection. Circulation 2003;107:2766-8.
28. Shimokawa H. Primary endothelial dysfunction: Atherosclerosis. J Mol Cell Cardiol 1999;31:23-37.
29. Duchna HW, Stoohs R, Guilleminault C, Christine Anspach M, Schultze-Werninghaus G, Orth M. Vascular endothelial dysfunction in patients with mild obstructive sleep apnea syndrome. Wien Med Wochenschr 2006;156:596-604.
30. Bayram NA, Ciftci B, Keles T, et al. Endothelial function in normotensive men with obstructive sleep apnea before and 6 months after CPAP treatment. Sleep 2009;32:1257-63.
31. Oflaz H, Cuhadaroglu C, Pamukcu B, et al. Endothelial function in patients with obstructive sleep apnea syndrome but without hypertension. Respiration 2006;73:751-6.
32. Ip MS, Lam B, Ng MM, Lam WK, Tsang KW, Lam KS. Obstructive sleep apnea is independently associated with insulin resistance. Am J Respir Crit Care Med 2002;165:670-6.
33. Gami AS, Caples SM, Somers VK. Obesity and obstructive sleep apnea. Endocrinol Metab Clin North Am 2003;32:869-94.
34. Iber C, Ancoli-Israel S, Chesson AL Jr., Quan SF The AASM Manual for the Scoring of Sleep and Associated Events: Rules, Terminology and Technical specifications. 1st ed. Westchester, IL: American Academy of Sleep Medicine, 2007.
35. Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002;39:257-65.
36. Cohn JN, Finkelstein S, McVeigh G, et al. Noninvasive pulse wave analysis for the early detection of vascular disease. Hypertension 1995;26:503-8.
37. Kurnik PB. Circadian variation in the efficacy of tissue-type plasminogen activator. Circulation 1995;91:1341-6.
38. von Kanel R, Natarajan L, Ancoli-Israel S, Mills PJ, Loredo JS, Dimsdale JE. Day/Night rhythm of hemostatic factors in obstructive sleep apnea. Sleep 2010;33:371-7.
39. Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000;342:1792-801.
40. Schoenhard JA, Smith LH, Painter CA, Eren M, Johnson CH, Vaughan DE. Regulation of the PAI-1 promoter by circadian clock components: differential activation by BMAL1 and BMAL2. J Mol Cell Cardiol 2003;35:473-81.
41. Uchiyama T, Kurabayashi M, Ohyama Y, et al. Hypoxia induces transcription of the plasminogen activator inhibitor-1 gene through genistein-sensitive tyrosine kinase pathways in vascular endothelial cells. Arterioscler Thromb Vasc Biol 2000;20:1155-61.
42. Pinsky DJ, Liao H, Lawson CA, et al. Coordinated induction of plasminogen activator inhibitor-1 (PAI-1) and inhibition of plasminogen activator gene expression by hypoxia promotes pulmonary vascular fibrin deposition. J Clin Invest 1998;102:919-28.
43. Naito Y, Tsujino T, Kawasaki D, et al. Circadian gene expression of clock genes and plasminogen activator inhibitor-1 in heart and aorta of spontaneously hypertensive and Wistar-Kyoto rats. J Hypertens 2003;21:1107-15.
44. Ranby M, Bergsdorf N, Nilsson T, Mellbring G, Winblad B, Bucht G. Age dependence of tissue plasminogen activator concentrations in plasma, as studied by an improved enzyme-linked immunosorbent assay. Clin Chem 1986;32:2160-5.
45. Mehta J, Mehta P, Lawson D, Saldeen T. Plasma tissue plasminogen activator inhibitor levels in coronary artery disease: correlation with age and serum triglyceride concentrations. J Am Coll Cardiol 1987;9:263-8.
46. Berry RB, Budhiraja R, Gottlieb DJ, et al. Rules for scoring respiratory events in sleep: update of the 2007 AASM Manual for the Scoring of Sleep and Associated Events. Deliberations of the Sleep Apnea Definitions Task Force of the American Academy of Sleep Medicine. J Clin Sleep Med 2012;8:597-619.
47. Foster GE, Poulin MJ, Hanly PJ. Intermittent hypoxia and vascular function: implications for obstructive sleep apnoea. Exp Physiol 2007;92:51-65.
48. Lavie L. Obstructive sleep apnoea syndrome-an oxidative stress disorder. Sleep Med Rev 2003;7:35-51.
49. Cohen MC, Rohtla KM, Lavery CE, Muller JE, Mittleman MA. Metaanalysis of the morning excess of acute myocardial infarction and sudden cardiac death. Am J Cardiol 1997;79:1512-6.
50. Ishibashi Y, Osada N, Sekiduka H, et al. Peak time of acute coronary syndrome in patients with sleep disordered breathing. J Cardiol 2009;53:164-70.
51. Buchner NJ, Sanner BM, Borgel J, Rump LC. Continuous positive airway pressure treatment of mild to moderate obstructive sleep apnea reduces cardiovascular risk. Am J Respir Crit Care Med 2007;176:1274-80.
52. Doherty LS, Kiely JL, Swan V, McNicholas WT. Long-term effects of nasal continuous positive airway pressure therapy on cardiovascular outcomes in sleep apnea syndrome. Chest 2005;127:2076-84.
53. Milleron O, Pilliere R, Foucher A, et al. Benefits of obstructive sleep apnoea treatment in coronary artery disease: a long-term follow-up study. Eur Heart J 2004;25:728-34.